Steven D Vold1, Laurie Dustin. 1. Boozman-Hof Regional Eye Clinic, PA, 3737 West Walnut, Rogers, AR 72756, USA.
Abstract
BACKGROUND AND OBJECTIVE: To report the impact of prior laser trabeculoplasty on clinical outcomes of Trabectome (NeoMedix Corporation, Tustin, CA) surgery. PATIENTS AND METHODS: This is a retrospective, non-comparative study of consecutive cases of Trabectome surgery with 36 months of follow-up. Main outcome measures were intraocular pressure (IOP), number of glaucoma medications, and the occurrence of secondary procedures. RESULTS: In the trabeculoplasty group, mean IOP measured 16.5 +/- 4.0 mm Hg with an average decrease of 24% from preoperative IOP at 12 months. In eyes without previous trabeculoplasty, IOP measured 15.7 +/- 3.0 mm Hg with an average decrease of 30% at 12 months. Adjunctive medications decreased to 2.1 and 1.5 glaucoma medications, respectively. Secondary procedures were performed in 12% and 10% of eyes in each group. CONCLUSION: Previous laser trabeculoplasty does not appear to significantly impact IOP, but may increase the need for glaucoma medication in patients undergoing Trabectome surgery.
BACKGROUND AND OBJECTIVE: To report the impact of prior laser trabeculoplasty on clinical outcomes of Trabectome (NeoMedix Corporation, Tustin, CA) surgery. PATIENTS AND METHODS: This is a retrospective, non-comparative study of consecutive cases of Trabectome surgery with 36 months of follow-up. Main outcome measures were intraocular pressure (IOP), number of glaucoma medications, and the occurrence of secondary procedures. RESULTS: In the trabeculoplasty group, mean IOP measured 16.5 +/- 4.0 mm Hg with an average decrease of 24% from preoperative IOP at 12 months. In eyes without previous trabeculoplasty, IOP measured 15.7 +/- 3.0 mm Hg with an average decrease of 30% at 12 months. Adjunctive medications decreased to 2.1 and 1.5 glaucoma medications, respectively. Secondary procedures were performed in 12% and 10% of eyes in each group. CONCLUSION: Previous laser trabeculoplasty does not appear to significantly impact IOP, but may increase the need for glaucoma medication in patients undergoing Trabectome surgery.